Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Kim

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The American Journal of Medicine|July 19, 2017
Ten Most Important Things to Know About Caring for Transgender PatientsStuart R Chipkin, Fred Kim
Aging and Disease|January 25, 2024
Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive DisordersAshish Kumar, Fred Kim, Dong-Keun Song, et al.
Alzheimer'S Research & Therapy|July 8, 2022
Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actionsByung Woo Kang, Fred Kim, Joon-Yong Cho, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentFred Kim, Tianyang Xi, Han Joo Lee, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 11, 2024
Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in ratsFred Kim, Padmanabh Singh, Hyunji Jo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersJames Arthur Rock, Anna McGuffin, Tao Han, et al.
The Journal of Prevention of Alzheimer'S Disease|September 5, 2025
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's diseaseDavid Greeley, Marshall Nash, Brad Herskowitz, et al.
Oncotarget|December 10, 2016
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabineCostantine Albany, Mary P Hever-Jardine, Katherine M von Herrmann, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The American Journal of Medicine|July 19, 2017
Ten Most Important Things to Know About Caring for Transgender PatientsStuart R Chipkin, Fred Kim
Aging and Disease|January 25, 2024
Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive DisordersAshish Kumar, Fred Kim, Dong-Keun Song, et al.
Alzheimer'S Research & Therapy|July 8, 2022
Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actionsByung Woo Kang, Fred Kim, Joon-Yong Cho, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentFred Kim, Tianyang Xi, Han Joo Lee, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 11, 2024
Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in ratsFred Kim, Padmanabh Singh, Hyunji Jo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersJames Arthur Rock, Anna McGuffin, Tao Han, et al.
The Journal of Prevention of Alzheimer'S Disease|September 5, 2025
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's diseaseDavid Greeley, Marshall Nash, Brad Herskowitz, et al.
Oncotarget|December 10, 2016
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabineCostantine Albany, Mary P Hever-Jardine, Katherine M von Herrmann, et al.
Pageof 1